Adelaide Research & Scholarship: Search

Search

Results 1-6 of 6 (Search time: 0.001 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2016	ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment	Eadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
	2016	TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy	Nievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
	2016	Chronic myeloid leukemia: reminiscences and dreams	Mughal, T.; Radich, J.; Deininger, M.; Apperley, J.; Hughes, T.; Harrison, C.; Gambacorti-Passerini, C.; Saglio, G.; Cortes, J.; Daley, G.
	2016	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients	Deininger, M.; Hodgson, J.; Shah, N.; Cortes, J.; Kim, D.; Nicolini, F.; Talpaz, M.; Baccarani, M.; Müller, M.; Li, J.; Parker, W.; Lustgarten, S.; Clackson, T.; Haluska, F.; Guilhot, F.; Kantarjian, H.; Soverini, S.; Hochhaus, A.; Hughes, T.; Rivera, V.; et al.
	2016	BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia	Latham, S.; Bartley, P.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.
	2016	ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines	Eadie, L.; Hughes, T.; White, D.; Eaves, C.